Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 7/20 | 0.66 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.59 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.59 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.59 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.58 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.58 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30876339 | 0.92 | OPRD1 (0.58) | OPRD1OPRM1NMUR2KEAP1 | |
| SCHEMBL29386868 | 0.84 | OPRD1 (0.82) | OPRD1NTSR1OPRM1 | |
| SCHEMBL31332244 | 0.84 | CXCL8 (0.64) | — | |
| SCHEMBL29462878 | 0.83 | OPRK1 (0.54) | OPRD1OPRM1 | |
| SCHEMBL31501224 | 0.83 | OPRK1 (0.54) | OPRD1OPRM1 | |
| Analog Of Dynorphin A SCHEMBL29389694 | 0.83 | OPRD1 (0.86) | OPRD1NTSR1NTSR2OPRM1 | |
| Dynorphin A (1-11) SCHEMBL30132402 | 0.83 | OPRD1 (0.86) | OPRD1NTSR1NTSR2OPRM1 | |
| SCHEMBL31332122 | 0.82 | CALCR (0.64) | OPRD1NTSR1OPRM1 | |
| SCHEMBL29878209 | 0.82 | OPRD1 (0.85) | OPRD1NTSR1NTSR2OPRM1 | |
| SCHEMBL1062481 | 0.82 | OPRK1 (0.56) | OPRD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119185569-A | Sustained release delivery system comprising a traceless linker | 诺华股份有限公司 | 2024-12-27 | — | — | CN | claimed |
| US-12433949-B2 | Sustained release delivery systems comprising traceless linkers | NOVARTIS AG (CH) | 2025-10-07 | — | — | US | disclosed |
| EP-4596689-A1 | ENZYME AGENT AND USE THEREOF | Amano Enzyme Inc. (JP) | 2025-08-06 | — | — | EP | disclosed |
| CN-120092086-A | Enzyme agent and application thereof | 天野酶制品株式会社 | 2025-06-03 | — | — | CN | disclosed |
| CN-119185569-A | Sustained release delivery system comprising a traceless linker | 诺华股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2024-11-14 | — | — | US | disclosed |
| WO-2024071388-A1 | ENZYME AGENT AND USE THEREOF | 天野エンザイム株式会社 | 2024-04-04 | — | — | WO | disclosed |
| US-20230201353-A1 | SUSTAINED RELEASE DELIVERY SYSTEMS COMPRISING TRACELESS LINKERS | NOVARTIS AG (CH) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201353-A1 | SUSTAINED RELEASE DELIVERY SYSTEMS COMPRISING TRACELESS LINKERS | ABCB11, ABCB1, GHRHR | OPRD1 3378/4885AGTR2 930/4885AGTR1 653/4885 |
| US-12433949-B2 | Sustained release delivery systems comprising traceless linkers | ABCB11, ABCB1, GHRHR | OPRD1 3378/4885AGTR2 930/4885AGTR1 653/4885 |
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | SCTR, GIPR, APLNR | OPRD1 501/4885AGTR2 100/4885AGTR1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.